CTOs on the Move

PopHealthCare

www.pophealthcare.com

 
At PopHealthCare, we believe healthcare should be personal. For us, that means bringing care to those who need it most, where they will be able to achieve their health goals best–at home or wherever they reside. Using in-home assessments and cutting-edge analytics, we identify high-risk patients and partner with health plans to keep them out of the hospital with our care team of compassionate, smart, deeply committed healthcare providers available 24/7. This commitment and integrity expands to all areas of our business. With over 22 clients in 17 states, PopHealthCare offers a fully integrated approach to care delivery, risk adjustment ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
Kevin Hiler
Chief Information Officer Profile

Similar Companies

Sinai Residences

Sinai Residences is a retirement community in Boca Raton that offers luxurious surroundings and a culture of sophistication. They provide top-notch independent and assisted living, memory care, rehab, and skilled nursing services on site.

MHO Labs

MHO Labs is a Commerce City, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vibrant Health

Vibrant Health is a company that sells health and wellness products online, including supplements, superfoods, and more.

Optics Institute of Southern California

Optics Institute of Southern California is a Tustin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diagnocure

DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.